Acquisition by Jeffrey Meckler of 75000 shares of Indaptus Therapeutics at 1.105 subject to Rule 16b-3

INDP Stock  USD 1.01  0.03  3.06%   
Slightly above 71 percent of all Indaptus Therapeutics' retail investors are curious in acquiring. The analysis of the overall investor sentiment regarding Indaptus Therapeutics suggests that quite a few traders are confidant. Indaptus Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Indaptus Therapeutics. Many technical investors use Indaptus Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Indaptus Therapeutics Director, Officer: Ceo And Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Acquisition of 75000 stock option (right to buy) at 1.105 of Indaptus Therapeutics by Jeffrey Meckler on 9th of October 2024. This event was filed by Indaptus Therapeutics with SEC on 2024-10-09. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Indaptus Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Indaptus Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Indaptus Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Indaptus Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Indaptus Therapeutics Fundamental Analysis

We analyze Indaptus Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Indaptus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Indaptus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Debt

Total Debt Comparative Analysis

Indaptus Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Indaptus Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Indaptus Therapeutics stock to make a market-neutral strategy. Peer analysis of Indaptus Therapeutics could also be used in its relative valuation, which is a method of valuing Indaptus Therapeutics by comparing valuation metrics with similar companies.

Peers

Indaptus Therapeutics Related Equities

ASMBAssembly Biosciences   1.86   
0%
12.0%
ANEBAnebulo Pharmaceuticals   0.72   
0%
4.0%
TPSTTempest Therapeutics   2.35   
15.0%
0%
REVBRevelation Biosciences   2.38   
15.0%
0%
RZLTRezolute   3.23   
21.0%
0%
KPRXKiora Pharmaceuticals   3.57   
23.0%
0%
FBRXForte Biosciences   3.88   
25.0%
0%
LGVNLongeveron LLC   5.10   
33.0%
0%
ABVCABVC Biopharma   5.38   
35.0%
0%
RNXTRenovoRx   6.38   
41.0%
0%
KTTAPasithea Therapeutics   6.46   
42.0%
0%
VRAXVirax Biolabs   8.82   
57.0%
0%
QNRXQuoin Pharmaceuticals   10.40   
68.0%
0%
NTRBNutriband   15.29   
100.0%
0%

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.